Thiodigalactoside TDG|cas:51555-87-4|西域试剂

Thiodigalactoside TDG,99.0%

产品编号：Bellancom-130208| CAS NO：51555-87-4| 分子式：C₁₂H₂₂O₁₀S| 分子量：358.36

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-130208		￥1950.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Thiodigalactoside TDG

产品介绍

Thiodigalactoside (TDG) 是一种具有口服活性的，有效的半乳凝素 (GAL) 抑制剂，对于 GAL-1 和 GAL-3 的 K_d 值分别为 24 μM，49 μM。Thiodigalactoside 是一种不可代谢的二糖，具有抗炎和抗癌活性。Thiodigalactoside 可显着降低饮食诱发的肥胖大鼠的体重增加。

生物活性

Thiodigalactoside (TDG) is an orally active and potent galectin (GAL) inhibitor with K_d values of 24 μM, 49 μM for GAL1 and GAL3, respectively. Thiodigalactoside, a non-metabolizable disaccharide, has anti-inflammatory and anti-cancer activity. Thiodigalactoside dramatically reduces body weight gain in diet-induced obese rats.

体外研究

Thiodigalactoside (TDG; 250 and 500 μM) exhibits dose-dependent reduction of fat accumulation based on triglyceride (TG) content and Oil Red O (ORO) staining.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Thiodigalactoside (TDG; 5 mg/kg; IP; once per week for 5 weeks) results in dramatic inhibition of HFD-induced body weight gain.
Thiodigalactoside (5 mg/kg; oral; daily or weekly for 5 weeks) gave less reduction in body weight gain compare with i.p..

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Five-week-old Sprague-Dawley (SD) male rats
Dosage:	5 mg/kg
Administration:	IP; once per week for 5 weeks
Result:	Resulted in dramatic inhibition of HFD-induced body weight gain by inhibiting adipogenesis and lipogensis as well as by increasing expression of the proteins associated with thermogenesis and energy expenditure.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Five-week-old Sprague-Dawley (SD) male rats
Dosage:	5 mg/kg
Administration:	IP; once per week for 5 weeks
Result:	Resulted in dramatic inhibition of HFD-induced body weight gain by inhibiting adipogenesis and lipogensis as well as by increasing expression of the proteins associated with thermogenesis and energy expenditure.

性状

Solid

溶解性数据

In Vitro:

H₂O : 100 mg/mL (279.05 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.7905 mL	13.9525 mL	27.9049 mL
5 mM	0.5581 mL	2.7905 mL	5.5810 mL
10 mM	0.2790 mL	1.3952 mL	2.7905 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶